You are currently logged into
POZ Directory - My Account or Log Out
POZ POZ
  • Home
  • Basics
    • Basics
    • Introduction
    • HIV Transmission and Risks
    • HIV Testing
    • HIV Prevention
    • Newly Diagnosed
    • Starting HIV Treatment
    • HIV Medications
    • HIV Drug Assistance Programs
    • HIV and Liver Disease
    • VIH/SIDA en Español
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Videos
    • POZ at Home
    • POZ TV
    • POZ Stories
    • POZ 100
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • POZ Awards
    • POZ at 25
    • POZ 100
    • Advocacy
    • COVID-19
    • Criminalization
    • Cure
    • Long-Term Survivors
    • Newly Diagnosed
    • PrEP
    • Prevention
    • Undetectable (U=U)
    • Youth
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • POZ Focus
    • POZ en Español
    • Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • POZ Personals
    • POZ Stories
    • POZ 100
    • Community
    • AIDS Is Everyday
    • Forums
    • Polls
    • Surveys
    • Quizzes
    • Ask POZ
    • Services Directory
    • Calendar
    • Jobs
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Press Releases
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#IDWeek 2020

Tweet
  • Share

AstraZeneva COVID-19 vaccine production

Third COVID-19 Vaccine May Be Up to 90% Effective

The vaccine from the University of Oxford and AstraZeneca uses a chimpanzee adenovirus vector.

Bictegravir and Dolutegravir Tied to Metabolic Side Effects

These two integrase inhibitors are associated with high blood sugar and diabetes.

Study Sheds Light on Weight Gain After Switching to New Tenofovir

This may reflect loss of the weight-suppressing effect of the older version of the drug.

People Prefer Injectable Cabenuva After Switching From Oral Meds

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

Switching to Biktarvy Is a Success for African Americans With HIV

Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.

Antibodies binding to protein

Trogarzo Maintains Viral Load Suppression for Nearly 10 Years

Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.